

Pharmaceutical research and development: what do we

BMJ, The

345, e4348-e4348

DOI: 10.1136/bmj.e4348

Citation Report

#	ARTICLE	IF	CITATIONS
1	Medicine In The Thrall Of The Culture Of DrugsPharmageddon By Healy David Berkeley (CA) : University of California Press , 2012 302Âpp.; \$39.95. Health Affairs, 2012, 31, 2826-2828.	5.2	0
2	Lively Capital: Biotechnologies, Ethics, and Governance in Global Markets Kaushik Sunder Rajan Duke University Press 2012. Genomics Society and Policy, 2012, 8, .	0.2	0
3	Drug development: Innovation or imitation deficit?. BMJ, The, 2012, 345, e5880-e5880.	6.0	7
4	Pharmaceutical Sales Representatives and Patient Safety. Journal of General Internal Medicine, 2013, 28, 1394-1394.	2.6	1
5	Five Un-Easy Pieces of Pharmaceutical Policy Reform. Journal of Law, Medicine and Ethics, 2013, 41, 581-589.	0.9	14
6	ESPEN endorsed recommendations: Nutritional therapy in major burns. Clinical Nutrition, 2013, 32, 497-502.	5.0	264
7	Managing change to avoid unwanted outcomes. Marketing Review St Gallen, 2013, 30, 72-82.	0.6	0
8	Research Spotlight: Upcycling drugs for brain-related diseases: a sustainable future for targeted drug delivery. Therapeutic Delivery, 2013, 4, 435-438.	2.2	1
9	Decline in new drug launches: myth or reality? Retrospective observational study using 30â€¦years of data from the UK. BMJ Open, 2013, 3, e002088.	1.9	19
10	Hidden or misreported trial results cause widespread patient harm. BMJ, The, 2013, 347, f4393-f4393.	6.0	1
11	Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs. Journal of Law, Medicine and Ethics, 2013, 41, 590-600.	0.9	112
12	Drug Design and Discovery: Translational Biomedical Science Varies Among Countries. Clinical and Translational Science, 2013, 6, 409-413.	3.1	3
13	Parallel Problems: Applying Institutional Corruption Analysis of Congress to Big Pharma. Journal of Law, Medicine and Ethics, 2013, 41, 556-560.	0.9	4
14	Market spiral pricing of cancer drugs. Cancer, 2013, 119, 3900-3902.	4.1	77
15	When Everyone Is an Orphan: Against Adopting a U.S.-Styled Orphan Drug Policy in Canada. Accountability in Research, 2013, 20, 227-269.	2.4	22
16	Assigning value to medical algorithms: implications for personalized medicine. Personalized Medicine, 2013, 10, 577-588.	1.5	6
17	The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood, 2013, 121, 4439-4442.	1.4	546
18	NICE is dead; long live NICE. BMJ, The, 2013, 346, f2546-f2546.	6.0	4

#	ARTICLE	IF	CITATIONS
19	Long Term Effectiveness on Prescribing of Two Multifaceted Educational Interventions: Results of Two Large Scale Randomized Cluster Trials. PLoS ONE, 2014, 9, e109915.	2.5	10
20	Estimating the Potential Annual Welfare Impact of Innovative Drugs in Use in Switzerland. Frontiers in Public Health, 2014, 2, 48.	2.7	8
21	Business Model Innovation in the Pharmaceutical Industry: The Supporting Role of Organizational Design. SSRN Electronic Journal, 2014, , .	0.4	1
22	The Challenge of Patent Expiry: A Case Study of Pharmaceutical Industry. Mediterranean Journal of Social Sciences, 2014, , .	0.2	1
23	Open innovation: An opportunity for Pharmerging countries to close the technology gap?. Journal on Innovation and Sustainability, 2014, 5, 19.	0.3	0
24	Pharmaceutical regulation in Europe and its impact on corporate R&D. Health Economics Review, 2014, 4, 23.	2.0	23
25	Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ, The, 2014, 349, g5741-g5741.	6.0	55
26	Introduction. Journal of Health Politics, Policy and Law, 2014, 39, 689-690.	1.9	2
27	Regulators Should Better Leverage Effectiveness Standards to Enhance Drug Value. Pharmacotherapy, 2014, 34, 1005-1011.	2.6	0
28	Some current issues in the design of HIV noninferiority trials. Aids, 2014, 28, 1921-1929.	2.2	1
29	Affordability of cancer care in the United Kingdom â€“ Is it time to introduce user charges?. Journal of Cancer Policy, 2014, 2, 31-39.	1.4	28
30	Self-Fulfilling Prophecies of the European Knowledge-Based Bio-Economy: The Discursive Shaping of Institutional and Policy Frameworks in the Bio-Pharmaceuticals Sector. Journal of the Knowledge Economy, 2014, 5, 1-18.	4.4	34
31	Discovery of Innovative Therapeutics: Todayâ€™s Realities and Tomorrowâ€™s Vision. 2. Pharmaâ€™s Challenges and Their Commitment to Innovation. Journal of Medicinal Chemistry, 2014, 57, 5525-5553.	6.4	43
33	Patent wars: affordable medicines versus intellectual property rights. BMJ, The, 2014, 348, g1533-g1533.	6.0	5
34	How innovative are new drugs launched in the UK? A retrospective study of new drugs listed in the British National Formulary (BNF) 2001â€“2012. BMJ Open, 2014, 4, e006235.	1.9	18
35	Developing tomorrow's antipsychotics: the need for a more personalised approach. Advances in Psychiatric Treatment, 2014, 20, 3-12.	0.5	3
36	Nutrition artificielle en R�animation. Reanimation: Journal De La Societe De Reanimation De Langue Francaise, 2014, 23, 332-350.	0.1	8
38	Pharmaceutical Policy Reform in the Russian Federation. Journal of Health Politics, Policy and Law, 2014, 39, 691-705.	1.9	8

#	ARTICLE	IF	CITATIONS
39	The development speed paradox: can increasing development speed reduce R&D productivity?. Drug Discovery Today, 2014, 19, 209-214.	6.4	8
40	Why the Shift? Taking a Closer Look at the Growing Interest in Niche Markets and Personalized Medicine. World Medical and Health Policy, 2015, 7, 3-27.	1.6	8
41	Actions following adverse drug events – how do these influence uptake and utilisation of newer and/or similar medications?. BMC Health Services Research, 2015, 15, 498.	2.2	3
42	Clinical evidence inputs to comparative effectiveness research could impact the development of novel treatments. Journal of Comparative Effectiveness Research, 2015, 4, 203-213.	1.4	2
43	Reverse Innovation and Reverse Technology Transfer: From Made in China to Discovered in China in the Pharmaceutical Sector. Management International, 2015, 19, 49-69.	0.1	10
44	Comparison of United States and Canadian Glaucoma Medication Costs and Price Change from 2006 to 2013. Journal of Ophthalmology, 2015, 2015, 1-8.	1.3	16
45	Acupuncture in the Treatment of Headache: A Traditional Explanation of an Ancient Art. Headache, 2015, 55, 457-464.	3.9	13
46	Why do cancer drugs get such an easy ride?. BMJ, The, 2015, 350, h2068-h2068.	6.0	36
47	Can subcellular organization be explained only by physical principles?. Communicative and Integrative Biology, 2015, 8, e1009796.	1.4	4
48	How Good Is “Evidence” from Clinical Studies of Drug Effects and Why Might Such Evidence Fail in the Prediction of the Clinical Utility of Drugs?. Annual Review of Pharmacology and Toxicology, 2015, 55, 169-189.	9.4	58
49	Propofol as a transformative drug in anesthesia: insights from key early investigators. Drug Discovery Today, 2015, 20, 1012-1017.	6.4	20
50	How Important Is Mode of Administration in Treatments for Rheumatic Diseases and Related Conditions?. Current Rheumatology Reports, 2015, 17, 514.	4.7	8
51	Prescripci3n de medicamentos. FMC Formacion Medica Continuada En Atencion Primaria, 2015, 22, 9-32.	0.0	0
52	Why the drug development pipeline is not delivering better medicines. BMJ, The, 2015, 351, h5542.	6.0	34
53	Medicine – misuse™: Implications for health and environmental sustainability. Social Science and Medicine, 2015, 143, 81-87.	3.8	17
54	Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. Expert Review of Clinical Pharmacology, 2015, 8, 77-94.	3.1	108
55	Peering into the pharmaceutical “pipeline”: Investigational drugs, clinical trials, and industry priorities. Social Science and Medicine, 2015, 131, 322-330.	3.8	51
56	Can medical products be developed on a non-profit basis? Exploring product development partnerships for neglected diseases. Science and Public Policy, 2015, 42, 315-338.	2.4	20

#	ARTICLE	IF	CITATIONS
57	The use of generic medications for hepatitis C. Liver International, 2016, 36, 929-932.	3.9	24
59	New Formulations of Old Analgesics and Repurposing of Old Drugs as “New” Analgesics. Clinical Therapeutics, 2016, 38, 988-989.	2.5	1
60	Does Increased Spending on Pharmaceutical Marketing Inhibit Pioneering Innovation?. Journal of Health Politics, Policy and Law, 2016, 41, 157-179.	1.9	7
61	Anti-VEGF therapy in ophthalmology: a qualitative analysis of transformative drug development. Drug Discovery Today, 2016, 21, 1019-1026.	6.4	4
62	Hydrogen deuterium exchange mass spectrometry in biopharmaceutical discovery and development “ A review. Analytica Chimica Acta, 2016, 940, 8-20.	5.4	65
63	The High Cost of Prescription Drugs in the United States. JAMA - Journal of the American Medical Association, 2016, 316, 858.	7.4	445
64	The impact of research and development and marketing costs on the profitability of pharmaceutical companies of Tehran Stock Exchange using panel data 2001-2013. International Journal of Pharmaceutical and Healthcare Marketing, 2016, 10, 467-476.	1.3	1
65	Health Care's Ills: A Catholic Diagnosis. Linacre quarterly, The, 2016, 83, 402-422.	0.2	1
66	Harnessing positive placebo effect and minimize negative nocebo effect: the art of a healing profession. Pain, 2016, 157, 2390-2390.	4.2	5
67	It’s Not You, It’s Your (Old) Vagina: Osphe’s Articulation of Sexual Dysfunction. Sexuality and Culture, 2016, 20, 38-55.	1.5	3
68	Pharmacogenomics to Revive Drug Development in Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2016, 30, 59-64.	2.6	7
69	“Quantum Leap” in Photobiomodulation Therapy Ushers in a New Generation of Light-Based Treatments for Cancer and Other Complex Diseases: Perspective and Mini-Review. Photomedicine and Laser Surgery, 2016, 34, 93-101.	2.0	29
70	High cancer drug prices 4 years later”Progress and prospects. Cancer, 2017, 123, 1292-1297.	4.1	23
71	A mapping for managers: open innovation for R&D intensive SMEs in the life sciences sector. European Journal of Innovation Management, 2017, 20, 210-229.	4.6	9
72	Why highly effective drugs are not enough: the need for an affordable solution to eliminating HCV. Expert Review of Clinical Pharmacology, 2017, 10, 583-594.	3.1	33
73	Gifts and influence: Conflict of interest policies and prescribing of psychotropic medications in the United States. Social Science and Medicine, 2017, 172, 153-162.	3.8	38
74	Drug discovery. , 2017, , 281-420.		1
75	Access to Generic Medicines for Hepatitis C in South Africa: A Journey of Discovery. Medicine Access Point of Care, 2017, 1, maapoc.0000002.	1.0	0

#	ARTICLE	IF	CITATIONS
76	Linkage of Clinical Trial and Administrative Data: A Survey of Cancer Patient Preferences. <i>Current Oncology</i> , 2017, 24, 161-167.	2.2	16
77	A Perspective on the Cost of Cancer Care. , 2017, , 219-237.		0
78	Patients not patents: Drug research and development as a public enterprise. <i>European Journal of Clinical Investigation</i> , 2018, 48, e12875.	3.4	9
79	Direct-Acting Antivirals and Hepatitis C: The Ethics of Price and Rationing by Genotype. <i>Clinical Infectious Diseases</i> , 2018, 67, 983-984.	5.8	3
80	A systems-level analysis of drugâ€‘targetâ€‘disease associations for drug repositioning. <i>Briefings in Functional Genomics</i> , 2018, 17, 34-41.	2.7	10
81	Health Research Priority Setting: The Duties of Individual Funders. <i>American Journal of Bioethics</i> , 2018, 18, 6-17.	0.9	29
82	The â€‘American (cancer) patients firstâ€‘plan to reduce drug pricesâ€‘A critical assessment. <i>American Journal of Hematology</i> , 2018, 93, 1444-1450.	4.1	3
83	Similar or the Same? Why Biosimilars are not the Solution. <i>Journal of Law, Medicine and Ethics</i> , 2018, 46, 776-790.	0.9	7
85	Orphan Drugs and Their Impact on Pharmaceutical Development. <i>Trends in Pharmacological Sciences</i> , 2018, 39, 525-535.	8.7	43
86	Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia. <i>American Journal of Epidemiology</i> , 2018, 187, 1990-2001.	3.4	8
87	Pharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics. <i>Journal of Public Health</i> , 2018, 40, 646-651.	1.8	10
89	<scp>FDA</scp> Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals. <i>Pharmacotherapy</i> , 2018, 38, 967-980.	2.6	9
90	Health, transatlantic trade, and President Trump's populism: what American Patients First has to do with Brexit and the NHS. <i>Lancet, The</i> , 2018, 392, 447-450.	13.7	6
91	Trump blames free riding foreign states for high US drug prices. <i>BMJ: British Medical Journal</i> , 2018, 360, k1088.	2.3	3
92	Can public financing of the private sector defeat antimicrobial resistance?. <i>Journal of Public Health</i> , 2019, 41, 422-426.	1.8	5
93	Less Is More: Norwegian Drug Regulation, Antibiotic Policy, and the â€‘Need Clauseâ€‘. <i>Milbank Quarterly</i> , 2019, 97, 762-795.	4.4	18
94	Corporate Logic in Clinical Care: The Case of Diabetes Management. <i>Medical Anthropology Quarterly</i> , 2019, 33, 463-482.	1.4	9
95	Predicting complexation performance between cyclodextrins and guest molecules by integrated machine learning and molecular modeling techniques. <i>Acta Pharmaceutica Sinica B</i> , 2019, 9, 1241-1252.	12.0	63

#	ARTICLE	IF	CITATIONS
96	The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework. Journal of Market Access & Health Policy, 2019, 7, 1583536.	1.5	13
97	Impact of Cost on the Safety of Cancer Pharmaceuticals. Cancer Treatment and Research, 2019, 171, 1-20.	0.5	3
98	Cross-national drug price comparisons with economic weights in external reference pricing in Germany. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 37-43.	1.4	8
99	The opportunity cost of pharmaceutical price increases: improving health by investing in education. Critical Public Health, 2019, 29, 353-362.	2.4	1
100	Automated Machine Learning Diagnostic Support System as a Computational Biomarker for Detecting Drug-Induced Liver Injury Patterns in Whole Slide Liver Pathology Images. Assay and Drug Development Technologies, 2020, 18, 1-10.	1.2	17
101	The Launch of the European Patients' Academy on Therapeutic Innovation in the Netherlands: A Qualitative Multi-Stakeholder Analysis. Frontiers in Medicine, 2020, 7, 558.	2.6	3
102	Disclosing conflict of interest does not mitigate healthcare bias and harm: It is time to sever industry ties. European Journal of Clinical Investigation, 2020, 50, e13344.	3.4	0
103	The Ethics of Precision Rationing: Human Genetics and the Need for Debate on Stratifying Access to Medication. Public Health Genomics, 2020, 23, 149-154.	1.0	2
104	Research and Development Costs of New Drugs. JAMA - Journal of the American Medical Association, 2020, 324, 516.	7.4	6
105	Strategic Patenting by Pharmaceutical Companies – Should Competition Law Intervene?. IIC International Review of Intellectual Property and Competition Law, 2020, 51, 1062-1085.	0.2	19
106	Pharmaceutical lobbying and pandemic stockpiling: A feeling of déjà vu in the Nordic countries and why the sociological perspective is crucial to understand COVID-19. Acta Sociologica, 2020, 63, 439-442.	1.9	2
107	Challenges and Opportunities for Drug Discovery in Developing Countries: The Example of Cutaneous Leishmaniasis. ACS Medicinal Chemistry Letters, 2020, 11, 2058-2062.	2.8	16
108	A Triple Helix systems perspective of UK drug discovery and development: A systematic review of REF impact case studies. Industry and Higher Education, 2021, 35, 650-666.	2.2	3
109	Colombian Contributions Fighting Leishmaniasis: A Systematic Review on Antileishmanials Combined with Chemoinformatics Analysis. Molecules, 2020, 25, 5704.	3.8	3
110	International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts. Social Science and Medicine, 2020, 255, 113005.	3.8	5
111	Trade agreements and the risks for the nursing workforce, nursing practice and public health: A scoping review. International Journal of Nursing Studies, 2020, 109, 103676.	5.6	2
112	Documenting the financialisation of the pharmaceutical industry. Social Science and Medicine, 2020, 258, 113096.	3.8	21
113	Addressing Health Care Disparities: A Radical Perspective and Proposal. Frontiers in Sociology, 2020, 5, 29.	2.0	3

#	ARTICLE	IF	CITATIONS
114	A Critical Discourse Analysis of Intellectual Property Rights Within NAFTA 1.0: Implications for NAFTA 2.0 and for Democratic (Health) Governance in Canada. International Journal of Health Services, 2020, 50, 278-291.	2.5	2
115	When are Pharmaceuticals Priced Fairly? An Alternative Risk-Sharing Model for Pharmaceutical Pricing. Health Care Analysis, 2020, 28, 121-136.	2.2	4
116	The moral economy of the pharmaceutical industry: Legitimising prices. Health (United Kingdom), 2021, 25, 271-287.	1.5	3
117	Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis. Health Economics Review, 2021, 11, 4.	2.0	12
118	The Oversight of Clinical Innovation in a Medical Marketplace. , 2021, , 287-295.		0
120	COMBACTE LAB-Net: building a European laboratory network for clinical trials on anti-infectives. Future Microbiology, 2021, 16, 635-647.	2.0	0
121	COVID-19, IP and access: Will the current system of medical innovation and access to medicines meet global expectations?. Journal of Generic Medicines, 2021, 17, 61-70.	0.2	4
123	STRATEGIES OF EMERGING COUNTRIES TO EXPAND THE OPERATIONS TO THE GLOBAL MARKET OF BIOPHARMACEUTICALS. Indian Drugs, 2021, 58, 07-18.	0.1	0
124	The rebirth of psychosocial importance in a drug-filled world.. American Psychologist, 2016, 71, 781-791.	4.2	7
126	Enabling Policy Planning and Innovation Management through Patent Information and Co-Authorship Network Analyses: A Study of Tuberculosis in Brazil. PLoS ONE, 2012, 7, e45569.	2.5	31
127	BRIC Health Systems and Big Pharma: A Challenge for Health Policy and Management. International Journal of Health Policy and Management, 2018, 7, 201-206.	0.9	11
128	Strengthening the Theory of Institutional Corruptions: Broadening, Clarifying, and Measuring. SSRN Electronic Journal, 0, , .	0.4	11
129	Clinical Trials and the Drive to Material Standardisation. Science and Technology Studies, 0, , 30-44.	0.7	8
130	Industry-funded clinical trials: Beneficial or harmful?. Clinical Research and Regulatory Affairs, 2015, 32, 109-112.	2.1	2
131	Bactericidal activity of propylene glycol, glycerine, polyethylene glycol 400, and polyethylene glycol 1000 against selected microorganisms. Journal of International Society of Preventive and Community Dentistry, 2015, 5, 114.	1.0	101
132	R&D Costs of New Medicines: A Landscape Analysis. Frontiers in Medicine, 2021, 8, 760762.	2.6	26
135	Teaching the Sensitive Stuff: Does Industry Matter? Issues in Corporate Social Responsibility and Sustainability. CSR, Sustainability, Ethics & Governance, 2015, , 147-175.	0.3	0
136	The Impact of Governmental Policy on R&D Projects in the Pharmaceutical Industry. SSRN Electronic Journal, 0, , .	0.4	0



#	ARTICLE	IF	CITATIONS
137	Business Model Innovation in the Pharmaceutical Industry. , 2015, , 240-268.		3
138	Big Pharma Entanglement with Biomedical Science. , 2016, , 213-243.		0
139	The Commercial Culture of Medicine. , 2016, , 175-212.		1
140	Sources of Harm. , 2016, , 133-173.		0
141	Pharmacoeconomics as a Response to Market Failure: An International Perspective. , 2016, , 269-279.		0
142	The Business of Healthcare. , 2018, , 241-294.		0
143	The impact of generic medicines on the European pharmaceutical market: The example of Poland. <i>Ekonomia</i> , 2018, 23, 251-260.	0.1	0
144	Pharmamarketing, Strafrecht, Selbstregulierung â€“ EinfÃ¼hrung in den Band. , 2019, , 1-26.		0
145	Medizinische AutoritÃ¤t und Interessenkonflikt: Content is King. , 2019, , 209-241.		0
146	Emotional Disorders in Multiple Sclerosis. , 2018, , .		0
147	Impact of marketing costs and the research and development on the profitability of Egypt's pharmaceutical companies. , 2019, 1, 40-69.	0.0	0
148	Digital Pills and Promises. , 2019, , .		1
149	Incorporation of knowledge through acquisition in the pharmaceutical industry. <i>Revista Brasileira De InovaÃ§Ã£o</i> , 0, 19, e0200016.	0.2	0
151	Innovation crisis in the pharmaceutical industry? A survey. <i>SN Business &amp; Economics</i> , 2021, 1, 1.	1.1	11
152	Current Science and the Black Hole Connection. <i>Advances in Media, Entertainment and the Arts</i> , 2022, , 279-305.	0.1	0
153	Enhancing organisational innovation capability â€“ A practice-oriented insight for pharmaceutical companies. <i>Technovation</i> , 2022, 115, 102461.	7.8	9
155	Four scenarios for the future of medicines and social policy in 2030. <i>Drug Discovery Today</i> , 2022, 27, 2252-2260.	6.4	5
156	Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe. <i>International Journal of Health Policy and Management</i> , 2022, , .	0.9	5

#	ARTICLE	IF	CITATIONS
157	Diversity, Profit, Control: An Empirical Study of Industry Employees' Views on Ethics in Private Sector Genomics. <i>AJOB Empirical Bioethics</i> , 2022, , 1-13.	1.6	13
158	Continuous IV Infusion of 5-Fluorouracil in Heavily Pretreated Metastatic Castrate-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 586-590.	1.9	1
159	Dividend policy issues in the European pharmaceutical industry: new empirical evidence. <i>European Journal of Health Economics</i> , 0, , .	2.8	0
160	Drug delivery and in vivo absorption. , 2022, , 335-390.		0
161	Key Factors to Improve Pharmaceutical Industry's R&D Productivity: A Case Study of Iranian Pharmaceutical Holding. <i>Medical Journal of the Islamic Republic of Iran</i> , 0, , .	0.9	0
162	Drug discovery: Standing on the shoulders of giants. , 2023, , 207-338.		0
163	High drug prices are not justified by industry's spending on research and development. <i>BMJ, The</i> , 0, , e071710.	6.0	16
164	Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment. <i>Obesity</i> , 2023, 31, 1270-1279.	3.0	14
165	Patient engagement in drug development: configuring a new resource for generating innovation. <i>Critical Public Health</i> , 2023, 33, 506-517.	2.4	1
166	Essential medicines lists are for high income countries too. <i>BMJ, The</i> , 0, , e076783.	6.0	4
167	Evolution of antiseizure medication use and cost in the United States of America 2006â€“2021. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2023, 112, 128-138.	2.0	0
168	A novel Shiga toxin 2a neutralizing antibody therapeutic with low immunogenicity and high efficacy. <i>Antimicrobial Agents and Chemotherapy</i> , 0, , .	3.2	0